Navigation Links
TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
Date:10/12/2008

NATICK, Mass. and WASHINGTON, Oct. 12 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries, which are designed to confirm the performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System in real-world practice. The two-year pooled ARRIVE data showed that the TAXUS Stent reduced clinical restenosis in patients with diabetes as effectively as in patients without diabetes, with no incremental risk of myocardial infarction (MI) or stent thrombosis. Analysis of the data was presented by John M. Lasala, M.D., Ph.D., F.A.C.C., at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

"The ARRIVE diabetic subset data demonstrated that the TAXUS Stent mitigated the adverse effect of diabetes as a risk factor for restenosis and repeat procedures in the patients studied," said Dr. Lasala, Professor of Medicine, Washington University School of Medicine in St. Louis. "While the diabetic patients had more cardiac risk factors, comorbidity and higher mortality than non-diabetics, the rates of reintervention, MI and stent thrombosis in the ARRIVE 1 and 2 registries were similar in both groups, regardless of risk profile."

The pooled analysis included two-year data on 2,112 medication-requiring diabetic patients and 5,380 non-diabetic patients from the ARRIVE registry program. The population was further segmented into a higher-risk group(1) and a lower-risk group. Due to a significant increase in comorbid risk factors in patients with diabetes compared to non-diabetics, multivariate modeling and analysis was used to
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
2. TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
3. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
4. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
5. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
6. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
7. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
10. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
11. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Restore Health, a leading personalized medicine company ... it is now offering pharmacogenetics testing that provides ... upon their particular genetic makeup. Comprehensive medication management ... a patient,s genetics and their entire drug regimen.  ... this new service to healthcare providers and their ...
(Date:7/24/2014)... UNION CITY, Calif., July 24, 2014  Abaxis, Inc. ... manufacturing point-of-care blood analysis systems, today reported financial results ... First quarter overview: , Revenues of ... , Diluted EPS of $0.21, up 50% over ... , Medical market revenues of $7.2 million, up 20% ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... , WASHINGTON, Dec. 10 BioWorld Today ... Research and Manufacturers of America ( PhRMA ) that identifies 97 new ... conditions. , The report , which was released ahead of ... found that the 97 products in development include 23 vaccines and 54 ...
... , MILFORD, Mass., Dec. 10 ... that it is partnering with the NC BioNetwork Pharmaceutical ... NC, to educate and train students and workers in ... biopharmaceutical industry. The Pharmaceutical Center, which is a collaborative ...
Cached Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4
(Date:7/27/2014)... Bags underneath the eyes is one condition ... there are a range of new products now available from ... baggy eyes serum review that is now posted for adults ... the issues with baggy eyes and how the natural ingredients ... The guide also provides a detailed overview of the creams ...
(Date:7/27/2014)... The report, “Glass Fiber & ... Raw Material, By Manufacturing Process, By Application (Transportation, ... Geography – Global Trends & Forecast to 2019”, ... with an analysis and forecast by value and ... 107 figures spread through 347 slides and in-depth ...
(Date:7/27/2014)... Prominent Vancouver Chiropractors, Dr. Shervin Ranjbar and ... hamstring release procedure in Vancouver, BC. Both these chiropractors ... and have years of experience in the field of ... by the two professionals using a foam roller exercise. ... release tight hamstrings and relieve the client of the ...
(Date:7/27/2014)... City (Sunday July 27 11:45 am ET): ... at the surgical sitehas been reduced by 77 ... in the American College of Surgeons National Surgical ... new case study presented at the 2014 ACS ... British Columbia, reportedly reduced its rate of cardiac ...
(Date:7/27/2014)... 2014 Metachromatic leukodystrophy (MLD, also ... disease which is commonly listed in the family ... as it affects the metabolism of sphingolipids. Leukodystrophies ... fatty covering which acts as an insulator around ... systems. MLD involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, ...
Breaking Medicine News(10 mins):Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Renowned Vancouver Chiropractors Demonstrates Hamstring Release in Vancouver, BC 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 3Health News:Surgical safety program greatly reduces surgical site infections for heart operations 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5
... Hospital today became the first in Ontario to implant a small ... about the size of a Zippo lighter is the ... highest level of energy, 40 joules. The narrow shape ... incision in the patient,s chest, which should mean a faster recovery ...
... , TUESDAY, Dec. 21 (HealthDay News) -- Like ... their sex, say researchers who spent 14 years observing a ... researchers found that both male and female chimpanzee youngsters play ... treat the sticks as would mothers caring for their infants. ...
... , TUESDAY, Dec. 21 (HealthDay News) -- Children ... independent in adulthood, new study findings suggest. For example, ... shoes in the bedroom or apples in the supermarket, according ... Kingdom. The study authors asked 20 children with autism ...
... , HOUSTON, Dec. 21, 2010 The day when an ... painless pill instead of a toxic drug cocktail is the ... Houston (UH) scientist. Preethi Gunaratne, assistant professor in ... of tiny genetic molecules known as microRNAs and pinpointing those ...
... morbidly obese persons face many health issues -- heart disease, ... chances of dying while driving during a severe auto accident ... vehicle crash, a moderately obese driver faces a 21 percent ... 56 percent increased risk of not surviving, according to a ...
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... discovered in recent years, losing a job is upsetting and ... But buck up. About a year later, the majority ... returned to their previous levels of happiness, a new study ...
Cached Medicine News:Health News:Young Female Chimps Use Sticks as 'Dolls' 2Health News:UH biochemist works to revolutionize ovarian cancer treatment 2Health News:UH biochemist works to revolutionize ovarian cancer treatment 3Health News:UH biochemist works to revolutionize ovarian cancer treatment 4Health News:Obesity increases risk of death in severe vehicle crashes, study shows 2Health News:Most People Regain Happiness After Job Loss 2Health News:Most People Regain Happiness After Job Loss 3
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
The Erythrocyte Sedimentation Rate (ESR) can be used as a nonspecific search technique in case of suspicion of inflammatory reactions as well as for judgement of their development. VACUETTE ESR tubes...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Glucose tubes contain an anti-coagulant and a stabiliser. The tubes are ideal for glucose and lactate determinations....
Medicine Products: